• Bacteriophage Therapy in Patients With Diabetic Foot Osteomyelitis

  NCT05177107

  TerminatedInterventionalPhase 2Updated Aug 19, 2025
• Bacteriophage Therapy TP-102 in Diabetic Foot Ulcers

  NCT04803708

  CompletedInterventionalPhase 1Phase 2Updated Oct 4, 2022
• Assessing the Efficacy of Anti-staphylococcal Phages in the Management of Infected Foot Ulcers in Diabetes

  NCT04289948

  WithdrawnInterventionalPhase 1Phase 2Updated Feb 28, 2020
• Bacteriophage Therapy TP-102 in Patients With Diabetic Foot Infection

  NCT05948592

  CompletedInterventionalPhase 2Updated Dec 22, 2025
• Phage Therapy for the Prevention and Treatment of Pressure Ulcers.

  NCT04815798

  Unknown statusInterventionalPhase 1Phase 2Updated Dec 21, 2021
• Evaluation of the Antibiofilmogramme® Test During Diabetic Foot Infections

  NCT02378493

  CompletedInterventionalNot ApplicableUpdated May 15, 2026

ClinicalTrials.gov ID

NCT02664740

Lead Sponsor

Centre Hospitalier Universitaire de NīmesOTHER

Overall Status

Not yet recruiting

Study Type

Interventional

Phase

Phase 1Phase 2

Enrollment

60Estimated

Last Update Posted

Mar 20, 2026Actual

Start Date

Sep 1, 2026Estimated

Primary Completion Date

Nov 2028Estimated

Completion Date

Nov 2028Estimated

Official Title

Comparison of the Efficacy of Standard Treatment Associated With Phage Therapy Versus Standard Treatment Plus Placebo for Diabetic Foot Ulcers Monoinfected by Staphylococcus Aureus: a Randomized, Multi-centre, Controlled, 2-parallel-group, Double-blind, Superiority Trial

Brief Summary

The primary objective of this study is to compare the efficacy of standard treatment associated with a topical anti-staphylococcal bacteriophage cocktail versus standard treatment plus placebo for diabetic foot ulcers monoinfected by methicillin-resistant or susceptible S. aureus (MRSA or MSSA) as measured by the relative reduction in wound surface area (%) at 12 weeks.

Detailed Description

The secondary objectives of this study are:

A. To compare the two study arms in terms of treatment safety and tolerance throughout the study.

B. To compare the two study arms in terms of further changes in wound healing at weeks 2, 4, 6, 8, 10, 12.

C. To describe the changes in the resistance and virulence of S. aureus (if present in the wound) from baseline to week 4, at modification of the first-line treatment or new antibiotic prescription (if any) and at week 12 if the wound is still not healed.

D. To describe in the two study arms the antibiotic resistance status of other bacteria isolated from wounds at week 4, at modification of the first-line treatment or new antibiotic prescription (if any) and at week 12 if the wound is still not healed.

E. To describe in the two study arms changes in wound microbiota from baseline to week 4, at modification of the first-line treatment or new antibiotic prescription (if any) and at week 12 if the wound is still not healed.

F. To describe the production of anti-phage antibodies during the topical treatment: baseline and week 4, at modification of the first-line treatment or new antibiotic prescription (if any), and at week 12.

G. Creation of a biobank for future ancillary studies (including, but not limited to, cytokine levels and cellular immune responses): days 0 and week 4, as well as week 12.

• Diabetic Foot
• Staphylococcal Infections

• Topical anti-Staphylococcus bacteriophage therapy
• Topical placebo corresponding to anti-Staphylococcus bacteriophage therapy

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Participant pre-inclusion criteria:

• The patient must have given his/her informed and signed consent

• The patient must be insured or beneficiary of a health insurance plan

• The patient is at least 18 years old

• The patient has type 1 or type 2 diabetes

• The patient is hospitalized/consulting in a participating centre

• The patient has a wound below the ankle that has be evolving for >2 weeks

• The patient has a neuropathic foot wound, classified S (0 or 1), I (0 or 1), N (1), B (1), A (0 or1) and D (1) according to the SINBAD classification,

  • without ischaemia or with non-critical ischaemia defined by: ankle arterial pressure > 50 mm Hg or toe systolic arterial pressure > 30 mm Hg or TcpO2 > 30 mm Hg )
  • with a surface area ≥ 0,5 cm2
  • With IWGDF/IDSA grade 2 or 3 infection without osteomyelitis (normal radiography*)

• Females of childbearing potential or Sexually active males with partner of childbearing potential: commitment to consistently and correctly use an acceptable method of birth control (oral, transdermal, systemic or implant contraception birth control, intrauterine devices) for 1 month after the last study drug administration

• Negative pregnancy test must be obtained before starting any experimental drug

• Females of non-childbearing potential: either surgically sterilized or at least 1 year postmenopausal (amenorrhea duration at least 12 months)

Participant final inclusion criteria:

• The patient has a neuropathic foot wound:

  • Classified S (0 or 1), I (0 or 1), N (1), B (1), A (0 or1) and D (1) according to the SINBAD classification,

• without ischaemia or with non-critical ischaemia defined by: ankle arterial pressure > 50 mm Hg or toe systolic arterial pressure > 30 mm Hg or TcpO2 > 30 mm Hg )

• with a surface area ≥ 0,5 cm2

  • With IWGDF/IDSA grade 2 or 3 infection without osteomyelitis

• The patient's wound is monoinfected by methicillin-resistant or susceptible S. aureus (MSSA or MRSA ), or infected by MSSA or MRSA and other bacteria (a total of 3 bacteria when accounting for MSSA or MRSA)

• The Phagogram of the patient demonstrated that the strains are susceptible to at least one phage(PP1493 and/or PP1815).

Participant pre-exclusion criteria:

• The patient is participating in, or has participated in over the past three months, another trial
• The patient is participating in, or has participated in over the past three months, another study that may interfere with the results or conclusions of this study
• The patient is in an exclusion period determined by a previous study
• The patient is under judicial protection, or is an adult under guardianship
• It is impossible to correctly inform the patient
• The patient refuses to sign the consent
• The patient is pregnant, parturient or breastfeeding. Patients should not be enrolled if they plan to become pregnant during the treatment period and 1 month after the last administration of study drug
• Women/Men refusing to use an effective contraception during and1 month after the last administration of study drug

Participant final exclusion criteria:

• The patient refuses to participate to the study
• The patient is pregnant, parturient or breastfeeding. Patients should not be enrolled if they plan to become pregnant during the treatment period and 1 month after the last administration of study drug
• Women/Men refusing to use an effective contraception during and1 month after the last administration of study drug
• Patients with diabetic foot wounds associated with clinical or radiographic signs of arthritis or osteomyelitis*
• Patient is not infected by S. aureus or infected by more than 3 bacteria even if the culture isolates a S. aureus.

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

Quadruple

Lead Sponsor

Centre Hospitalier Universitaire de NīmesOTHER

Collaborators

PhagenixINDUSTRY

s.rebaudet@hopital-europeen.fr